To investigate present and lifetime behavioural patterns in a group of adolescents (n = 26, mean age 12.9 years, range 10 to 16 years) with CD we used Baum and Walker's modifìed version of the Child Behaviour Checklist (CBCL), where parents are required to rate their children within 2 age periods: from birth to age 3 years (infancy) and from age 4 to age 10 years (childhood). The scores of the CD group were compared with those of a nonclinical group. From this study, CD seems to emerge during adolescence as a disturbance presenting a clear overlap between externalizing (score: 72) and internalizing (score: 68) dimensions. Such an overlap is still present during childhood when significant differences between childhood and adolescence do not emerge (internalizing score: 68 vs 68: P = 0.94; externalizing score: 72 vs 70: P = 0.32). From birth to age 3 years, the comparison between CD and the control group shows significantly higher mean scores for the CD group on both internalizing (63 vs 42: P < 0.001) and externalizing (57 vs 38: P < 0.001) scales, but with mean scores falling in the clinical range only for the internalizing dimension.
These data permit us to hypothesize that CD has both internalizing and externalizing antecedents during childhood, although families consult at adolescence only for externalizing symptoms. Our findings also support the hypothesis that CD has relevant symptoms in infancy, thus allowing us to underline the importance of early internalizing antecedents in CD. According to Aronen (2), the internalizing symptoms in our sample precede later externalizing problems. Luby also found an unexpectedly high level of internalizing psychopathology in a group of externalizing children under 5 years of age (3). This high level of internalizing psychopathology found in externalizing children might account for high rates of comorbidity and for difficulties in differential diagnosis with preschool children having bipolar disorders. The question of comorbidity with mood and anxiety disorders is very complex for CD, representing an area for further investigation that may have important clinical implications for treatment of young children with externalizing disorders. Moreover, depressive symptoms in childhood should be addressed to prevent later psychiatric problems, especially aggression, poor adaptive functioning, and low self-esteem (2) .
Finally, a heterotypic developmental continuity can be hypothesized (4), where internalizing problems first occur in infancy and externalizing problems emerge later during childhood and mature during adolescence, giving rise to a clinical pattern of mixed internalizing and externalizing disorder. This perspective seems to disconfirm the alternative hypothesis that internalizing symptoms emerge as a consequence of externalizing problems.
Filippo Muratori, MD Francesco Salvadori, MD Lara Picchi, PhD Annarita Milone, MD Pisa, Italy
Travel Time and the Use of Psychiatric Outpatient Clinic Services in Coastal Northern Norway
Dear Editor:
Studies from other countries have found that travel time is of importance to the utilization of psychiatric services, suggesting that most patients will not travel over 30 minutes for service (1) . Northern Norway is sparsely inhabited, and inhabitants are accustomed to travelling. We examined whether travel time was of importance to service utilisation at the outpatient clinic at Stokmarknes, Nordland. The catchment area comprises 2368 km 2 and had 31 629 inhabitants in 1997 (2) . The population is ethnic Norwegian, with a minority population of Samis and African and Asian refugees. Types of employment include administration, education, health services, private business, fishing, farming, and the military; 46% of the population live in 5 towns, with the remainder living in sparsely populated areas. The clinic also gives occasional consultations (that is, less than 10%) in general practitioner (GP) offices outside of Stokmarknes.
We retrospectively compared the clinic's record of patients treated from 1992 to 1996 with publicly available population figures (2) . Travel time was calculated from zip codes and from information gathered from local bus and ferry companies. Geographical factors made 35 minutes a natural division point.
Of the inhabitants, 10 996 (34.8%) had a travel time of 35 minutes or less (group 1). The remaining 20 633 inhabitants (65.2%) exceeded a travel time of 35 minutes (group 2). Of 1834 patients treated, 51.9% had a travel time of 35 minutes or less. A significantly higher proportion living within 35 minutes of the clinic had used the clinic's services (8.6% vs 4.3%, P 2 = 250, P < 0.001). The mean travel time in group 1 was 22.1 minutes (range 0 to 35 minutes); in group 2, it was 99.5 minutes (range 50 to 130 minutes). The mean age in group 1 was lower than in group 2 (40.5 vs 43.5 years). The percentage of women in group 1 was nonsignificantly higher (59.4% vs 56.4%, P 2 = 1.70).
In Norway, the number and level of activities in smaller local clinics has increased, following the belief that smaller local facilities are preferable to, and more accessible than, larger central facilities. However, little effort has been made to study whether local facilities are in fact sufficiently accessible to people in the catchment area. Although north Norwegians are accustomed to travelling longer distances to obtain specialized medical services, we find that travel time remains important to the use of psychiatric outpatient services. Though we lack information, we believe that a combination of fewer referrals and more missed appointments explains why the rate of utilization is lower in group 2 than in group 1. Other possible explanations are differences in mental health, tendency of people with mental illness to drift toward the towns, and higher tolerability toward persons with mental illness among GPs and other people in the periphery.
Kristoffer Skarsvåg, MD Rolf Wynn, MD, PhD Tromsø, Norway
Respiratory Panic Disorder Treatment With Clonidine

Dear Editor:
Clonidine is known to block alpha-2 receptors in the locus coeruleus, and for theoretical reasons, it would seem a good antipanic drug. Few clinical trials have been conducted with clonidine for the treatment of panic disorder (PD) (1, 2) . In a small series, two-thirds of patients initially responded, but the therapeutic effect tended to be lost in some weeks, despite continuation of dosage (1) . In this study, we report 2 cases of respiratory PD patients who were successfully treated with clonidine in the Laboratory of Panic and Respiration of Rio de Janeiro.
Case Report 1
Miss A is a white student, age 20 years. The patient began having panic attacks 3 years ago, with symptoms including sweating, shivering, tachycardia, dyspnea, and an intense fear lasting from 5 to 20 minutes. Two months before her first evaluation, the patient suffered new panic attacks with feelings of dyspnea, shortness of breath, tachycardia, fear of choking, and fear of dying. She described a fear of being home alone and of riding buses or other public transportation; she therefore avoided these situations. She underwent several laboratory examinations, all with normal results. She was initially treated with 0.15 mg daily of clonidine. After 6 weeks, she was taking 0.30 mg daily of clonidine and achieved full remission of the panic attacks and phobic avoidance. In the initial 2 weeks of treatment, the patient described feelings of mild dizziness and nausea.
Case Report 2
Miss C is a white college student, age 23 years. The patient described recurrent panic attacks during a 1-year period, with feelings of dizziness, tachycardia, trembling, heat spells, dyspnea, and a fear of becoming insane (lasting 10 to 15 minutes). The panic attacks occurred mainly in closed places, such as restaurants and bookstores. The patient discovered that by avoiding these situations she could decrease the frequency of the panic attacks, and she progressively interrupted all daily activities until she seldom left the house at all and developed an agoraphobic behaviour. Laboratory and clinical exams were normal. She was initially treated with 0.15 mg daily of clonidine, increased to 0.30 mg daily after 4 weeks of treatment, which fully remitted her panic attacks. At the sixth week of treatment, the patient continued her studies with the same dosage of 0.30 mg daily of clonidine. She described feelings of somnolence in the initial 2 weeks of treatment.
Both patients obtained panic-free status, reduced anxiety levels, and better functioning after clonidine administration for 6 weeks. An interesting finding is the remission of panic attacks with clonidine as early as the 4th week of treatment. Clonidine was well tolerated by the patients. All patients were classified as respiratory PD subtype, according to Briggs and colleagues' criteria (3). This subtype may have a favourable clinical response to clonidine. Because of its specific adrenergic action, clonidine may be an effective tool for investigating and elucidating abnormalities in a noradrenergic system in patients with PD, and it may play a role in relieving symptoms of anxiety caused by noradrenergic hyperactivity.
